You are here

P&T® Journal contents for July 2010

Features

Web Watch
As drug companies join social networking sites to promote their brands, they’ve been avoiding communicating sensitive information about specific products and potential adverse events. Until the FDA implements guidelines for advertising in the new social media, pharma will probably continue to play it safe as it wades into the twittersphere.
Miriam Reisman
How U.S. Hospitals and the Federal Government Are Working to Reduce Adverse Events
Although our nation’s blood supply has become safer and transfusion-associated risks have decreased, preventable errors still occur. Typing blood and cross-matching are complex procedures, but bar coding and radiofrequency identification are enhancing the safety of the blood supply at various hospitals.
Cindy H. Dubin
Despite treatment guidelines indicating that inhaled corticosteroid (ICS) therapy is effective and safe for mild-to-moderate persistent asthma, ICS monotherapy continues to be underused. Present prescribing patterns result in higher drug costs and may expose patients to safety risks.
Donald S. Beam, MD
Etiology, Diagnosis, and Treatment
Epilepsy affects more than 3 million people in the U.S. and about 50 million people worldwide. Because of the myriad types of seizures, choosing the right medication for each patient is essential. This article reviews approved and forthcoming agents and includes a comprehensive appendix showing warnings, adverse events, and contraindications.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
The Secondary Use of Data
Using health data for secondary purposes holds promise in improving patient outcomes and controlling costs. Respondents to a recent survey emphasize that electronic medical records must be linked to the right patients, data must be consolidated, and security and privacy must be guaranteed.
David B. Nash, MD, MBA
Medication Errors
Pharmacists who bypass computer alerts may have valid clinical reasons, but important warnings can be overridden or missed.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Congress Turns to Medical Price Transparency
The health care reform bill failed to address the hidden costs of hospital and home care, medications, and physician visits. A remedy may be forthcoming after hearings on several medical price transparency bills take place.
Stephen Barlas
FDA approvals, drug indications, product recalls, and devices in the news